CagriSema Phase 2 trial (NCT04982575)
Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 Diabetes
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 92
- actual
- Start
- 2 Aug 2021 (actual)
- Primary completion
- 7 Jul 2022 (actual)
- Sponsor
- Novo Nordisk A/S
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Cagrilintide 2.4 mg and semaglutide 2.4 mg | Experimental | Drug: Semaglutide 2.4 mg; Drug: Cagrilintide 2.4 mg | Participants will receive cagrilintide and semaglutide once a week as injections for 32 weeks. |
| Cagrilintide 2.4 mg and placebo (semaglutide) | Active comparator | Drug: Cagrilintide 2.4 mg; Drug: Placebo (semaglutide) | Participants will receive cagrilintide and placebo (semaglutide) once a week as injections for 32 weeks |
| Semaglutide 2.4 mg and Placebo (cagrilintide) | Active comparator | Drug: Semaglutide 2.4 mg; Drug: Placebo (cagrilintide) | Participants will receive semaglutide and placebo (cagrilintide) once a week as injections for 32 weeks |
Primary endpoint
| Measure | Time frame |
|---|---|
| Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide) | Week 0, Week 32 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Change in Glycated Haemoglobin (HbA1c): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide) | Week 0, Week 32 |
| Percentage Change in Body Weight: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide) | Week 0, Week 32 |
| Change in Body Weight (Kilogram): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide) | Week 0, Week 32 |
| Change in Fasting Plasma Glucose (FPG): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Semaglutide 2.4 mg + Placebo (Cagrilintide) | Week 0, Week 32 |
| CGM: Change in Mean Glucose: Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide) | Week 0, Week 32 |
| Percentage of Time Above Range (TAR) Greater Than 10.0 mmol/L (Greater Than 180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide) | At week 32 |
| Percentage of Time in Range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL) Measured Using CGM (Continuous Glucose Monitoring): Cagrilintide 2.4 mg + Semaglutide 2.4 mg Versus Cagrilintide 2.4 mg + Placebo (Semaglutide) | At week 32 |
| Number of Treatment Emergent Adverse Events (TEAEs) | From baseline (week 0) to week 37 |
| Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Below 3.0mmol/L (54mg/dL), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3) | From baseline (week 0) to week 37 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results are posted on the registry. Open the ClinicalTrials.gov record for NCT04982575.
How the CagriSema type 2 diabetes comparison was set up
This 32-week trial across 17 US sites randomised adults with type 2 diabetes 1:1:1 to CagriSema, semaglutide or cagrilintide, each escalated to 2.4 mg.[2]
Change in HbA1c from baseline was the primary endpoint, with bodyweight, fasting glucose, CGM measures and safety as secondary endpoints.[2]
Glycaemic, weight and safety results at week 32
HbA1c fell by 2.2 points with CagriSema, 1.8 with semaglutide and 0.9 with cagrilintide, and the CagriSema edge held against cagrilintide (p<0.0001) but not semaglutide (p=0.075).[2]
Bodyweight changed by -15.6% with CagriSema, -5.1% with semaglutide and -8.1% with cagrilintide.[2]
CGM time in range rose to 88.9%, 76.2% and 71.7% in the three arms respectively.[2]
Adverse events were reported by 68%, 71% and 80% of participants in the CagriSema, semaglutide and cagrilintide groups, mostly mild or moderate gastrointestinal events.[2]
Sources
- 1Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 11 Oct 2026
Found an error? Report a correction.